Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, announced that it had completed the first phase of a $7.3 million investment to upgrade and expand its packaging and softgel encapsulation capabilities at its facility in Aprilia (Italy).
The first phase of investment, completed in August 2018, saw the expansion and upgrade of the facility’s integrated packaging capabilities, and the commissioning of the first of five new softgel encapsulation lines. The second phase of the investment, to add a further four encapsulation lines, will bring the total number of lines to 23 and significantly expand production, drying, and inspection capacity for nutritional supplements and beauty softgels at the site. It is expected that these four new lines will be fully operational by January 2019.
Catalent RP Scherer Softgel is a global leader in innovative oral and topical softgel technologies for the pharmaceutical, consumer health, and beauty markets. Its softgel technologies are proven to solve complex bioavailability and formulation challenges, and are preferred in a wide range of consumer health and pharmaceutical product categories.
Catalent Pharma Solutions is a global provider of drug delivery technology and development solutions for drugs, biologics and consumer health products. Headquartered in Somerset, New Jersey (USA), Catalent operates 33 locations across five continents.